5.70Open5.70Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover599.06%IV-6.19%PremiumOct 18, 2024Expiry Date5.81Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7791Delta0.1584Gamma0.28Leverage Ratio-0.0212Theta-0.0018Rho-0.22Eff Leverage0.0009Vega
ProKidney Stock Discussion
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
No comment yet